Why Eli Lilly Stock Climbed to a New All-Time High Today
Written by Joe Tenebruso for The Motley Fool -> Investors are excited about retatrutide's potential. Rival drugmakers are finding it difficult to keep pace with the healthcare leader. Shares of Eli Lilly (NYSE: LLY) rose to a record high on Monday after the medicine maker anno
Rival drugmakers are finding it difficult to keep pace with the healthcare leader.
Shares of Eli Lilly (NYSE: LLY) rose to a record high on Monday after the medicine maker announced positive clinical trial results for its next-generation weight loss drug.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Retatrutide, Eli Lilly's investigational once-weekly injectable medication, targets three metabolic hormones to suppress appetite, control blood sugar, and support fat loss.
Results from Phase 3 trials showed that retatrutide led to substantial weight loss compared to placebo, along with meaningful improvements in common obesity-related conditions including knee pain, sleep apnea, and type 2 diabetes.
Trial participants on the highest (12 mg) dose of retatrutide lost an average of 70 pounds, or 28% of their body weight, over 80 weeks. Even at the lowest (4 mg) dose, people lost an average of 47 pounds (19%).
Importantly, the adverse events seen during the trials were generally mild to moderate and tended to resolve during treatment.
"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos...These findings demonstrate what may be possible when we treat obesity and impact overall health, and what this could mean for people living with obesity and its related complications," lead investigator Dr. Ania Jastreboff said in a press release.
